Role of AMPK-mTOR-Ulk1/2 in the Regulation of Autophagy: Cross Talk, Shortcuts, and Feedbacks

Sebastian Alers, Antje S. Löffler,* Sebastian Wesselborg,* and Björn Stork*

Department of Internal Medicine I, University Clinic of Tübingen, Tübingen, Germany

Living cells are adaptive self-sustaining systems. They strictly depend on the sufficient supply of oxygen, energy, and nutrients from the outside in order to sustain their internal organization. However, as autonomous entities they are able to monitor and appropriately adapt to any critical fluctuation in their environment. In the case of insufficient external nutrient supply or augmented energy demands, cells start to extensively digest their own interior. This process, known as macroautophagy, comprises the transport of cytosolic portions and entire organelles to the lysosomal compartment via specific double-membrane vesicles, called autophagosomes. Although extensively upregulated under nutrient restriction, a low level of basal autophagy is likewise crucial in order to sustain the cellular homeostasis. On the other hand, cells have to avoid excessive and enduring self-digestion. The delicate balance between external energy and nutrient supply and internal production and consumption is a demanding task. The complex protein network that senses and precisely reacts to environmental changes is thus mainly regulated by rapid and reversible posttranslational modifications such as phosphorylation. This review focuses on the serine/threonine protein kinases AMP-activated protein kinase, mammalian target of rapamycin (mTOR), and unc-51-like kinase 1/2 (Ulk1/2), three interconnected major junctions within the autophagy regulating signaling network.

AMPK: THE ENERGY-SENSING KINASE

AMP-activated protein kinase (AMPK) was initially identified as a serine/threonine kinase that negatively regulates several key enzymes of the lipid anabolism (30). Meanwhile, AMPK is regarded as the major energy-sensing kinase that activates a whole variety of catabolic processes in multicellular organisms such as glucose uptake and metabolism, while simultaneously inhibiting several anabolic pathways, such as lipid, protein, and carbohydrate biosynthesis (reviewed in reference 30).

AMPK is a heterotrimeric protein complex that is precisely regulated in different ways. First, the phosphorylation of a conserved threonine residue (T172) in the activation loop of the catalytic α-subunit by upstream kinases is a prerequisite for the activity of AMPK. Several AMPK-phosphorylating kinases have been identified thus far. In addition to the ubiquitously expressed and constitutively active kinase LKB1 (31, 109), Ca2+/calmodulin-dependent kinase kinase-1 (CaMKK) (32, 43, 108) and transforming growth factor β/activating kinase-1 (TAK1) (80) are both known as activators of AMPK. Second, AMPK activity can further be modulated by allosteric binding to the regulatory β- and γ-subunit. Since the ratio of AMP to ATP represents the most accurate way to precisely measure the intracellular energy level, both AMP and ATP are able to oppositely regulate the activity of AMPK. While AMP binding to the γ-subunit allosterically enhances AMPK kinase activity and prevents the dephosphorylation of T172, ATP is known to counteract the activating properties of AMP (30). Although ADP does not allosterically activate AMPK, it could be shown very recently that it also binds to AMPK and enhances phosphorylation at T172 (83, 111).

AMPK is an evolutionarily conserved energy-sensing kinase that is activated by metabolic stress or ATP consumption and that globally promotes catabolic processes. In accordance with that, AMPK could also be linked to the regulation of autophagy. Initially, the yeast ortholog of AMPK (SNF1) was identified as a positive regulator of autophagy (42, 107). The essential role of AMPK for the regulation of autophagic proteolysis in mammalian cells was confirmed subsequently, mainly by addressing long-lived protein degradation in HT-29 human colon cancer and HeLa cells (77). In addition to AMPK’s activation by low cellular energy levels, presumably via LKB1 and high AMP concentrations, it has been suggested that a variety of other non-starvation-related autophagy-inducing stimuli primarily act through the activation of AMPK even under normal energy levels (39, 40). Autophagy induction, observed after the rise in intracellular Ca2+ concentrations in human breast cancer and cervix carcinoma cells, has been linked to CaMKKβ-mediated enhancement of AMPK activity (39). Similarly, TRAIL-induced cytoprotective autophagy in nontransformed epithelial cells has been reported to depend on TAK1-mediated AMPK activation, and it has been argued that this may contribute to the differential cell death response of nontransformed versus tumor cells after TRAIL treatment (36). However, although the expression of a dominant-negative form of AMPK completely inhibited autophagic proteolysis in HT-29 and HeLa cells under harsh starvation conditions (Hanks balanced salt solution [HBSS]), transfection with a constitutively active form of AMPK did not affect the rate of autophagy (77). Thus, it is still not clear whether AMPK activation alone is sufficient to induce autophagy in mammalian cells or whether the basal activity of AMPK, although essential for autophagy induction, must be accompanied by additional cell stress pathways such as those triggered by TRAIL, an increase in intracellular [Ca2+], or nutrient and growth factor withdrawal (reviewed in reference 58).
As long as unicellular organisms live in the land of plenty, they will grow and divide. In multicellular organisms, cell growth and proliferation must also be tightly regulated by growth factor signaling to avoid neoplasm. However, cell growth and division only make sense when the cell is sufficiently supplied with energy and nutrients that serve as building blocks for biosynthesis. A key enzyme that balances diverse anabolic processes such as cell growth, proliferation, and protein synthesis in response to those growth-inducing stimuli is the target of rapamycin (TOR). As it turns out, the growth factor-regulated and nutrient-sensing kinase TOR and the energy-sensing kinase AMPK act in concert to control autophagy induction.

**mTOR: THE NUTRIENT-SENSING KINASE**

TOR was initially identified as a target for the antifungal properties of rapamycin, which leads to growth inhibition in *Saccharomyces cerevisiae* (35). Later, it was shown that TOR is also involved in the regulation of autophagy and that rapamycin is able to induce autophagy in yeast even under nutrient-rich conditions (82). TOR is an evolutionary highly conserved serine/threonine protein kinase and hence not only found in yeast but also in metazoans such as flies (dTOR) and mammals (mammalian target of rapamycin [mTOR]). *Drosophila* mutants deficient in dTOR exhibit reduced cell and body size (85, 120), as well as a massive accumulation of autophagic vesicles in the fat body even under fed conditions (92).

TOR proteins interact with several binding partners to form at least two functionally distinct complexes, called TOR complex 1 (TORC1) and TORC2 in yeast. Notably, rapamycin solely binds to TORC1, and only TORC1 deficiency resembles the effects of rapamycin treatment (110). The corresponding mammalian rapamycin-sensitive mTOR complex 1 (mTORC1) comprises mTOR, mLST8 (or GBl), PRAS40, and the regulatory-associated protein of TOR (raptor) (53). mTORC2, in contrast, is unaffected by rapamycin treatment since it comprises the rapamycin-insensitive companion of TOR (rictor) instead of raptor (91) (reviewed in references 94 and 110). Notably, while rapamycin is a strong autophagic stimulus in yeast, it poorly induces autophagy in mammalian cells. It could be demonstrated that this compound, although fully inhibiting the mTORC1-dependent phosphorylation of S6K, only partially inhibits the phosphorylation of other known mTORC1 substrates. Some mTORC1-dependent functions such as autophagy inhibition might thus be partially unaffected by rapamycin (101, 102). Using the ATP-competitive mTOR inhibitor Torin1, it could be shown that the above mentioned discrepancy to yeast is mainly due to those rapamycin-resistant functions of mTORC1 (101, 102). It has been argued that this might be the main reason for the limited success of rapamycin treatment in anticancer therapy (101).

While AMPK is activated under energy-low conditions, leading to autophagy induction, mTORC1 activity depends on diverse positive signals such as high energy levels, normoxia, amino acids, or growth factors that all result in the inhibition of autophagy.

Growth factors activate the PI3K/Akt pathway through receptor tyrosine kinases (RTK). Upon growth factor binding, Akt is recruited to the plasma membrane, where it is activated through phosphorylation by PDK1. Activated Akt in turn phosphorylates TSC2 (tuberous sclerosis complex 2), which prevents formation of the inhibitory TSC1/TSC2 heterodimer. Since TSC2 serves as a GTPase-activating protein (GAP) and inactivates the small GTPase Rheb, its inhibition subsequently allows Rheb to directly activate mTORC1 (41, 71, 72, 119). In addition, the mTORC1 component PRAS40 has been identified as a direct Akt substrate, and the data suggest that this phosphorylation is responsible for mTORC1 activation via insulin signaling (105). Hence, growth factor withdrawal would finally lead to mTORC1 inactivation and in turn to the induction of autophagy.

In addition to growth factor signaling, nutrient availability contributes to the positive regulation of mTORC1 activity. It has been suggested that amino acids activate mTORC1 via the Rag family of small GTPases (54, 90), whose activity is regulated by amino acids. However, unlike Rheb, Rag GTPases are not able to activate mTORC1 activity *in vitro* (90). This discrepancy might have been solved recently, since Sancak et al. showed that mTORC1 is recruited to lysosomes in a Rag-dependent manner upon amino acid stimulation, where it is finally activated by Rheb GTPases (89). This would explain how growth factor and amino acid signaling are integrated to fully activate mTORC1. In addition, mTORC1 activity has been shown to be regulated by oxygen concentrations (2). Hypoxia-induced inhibition of mTOR is even dominant over mTOR-activating signals such as growth factors and nutrients (2). It likewise seems to act via the TSC1/TSC2 complex and depends on transcriptional upregulation of REDD1 (7).

Energy levels are mainly sensed via the above described AMPK pathway. Activated AMPK was thought to inhibit mTORC1 activity primarily in the opposite way as growth factors stimulate it, mainly by phosphorylation and activation of the negative regulator TSC2 (44). However, the fact that TSC2-deficient cells still respond to decreasing energy levels led to the investigation of additional mechanisms. Raptor has meanwhile been identified as a direct substrate of AMPK. It could be demonstrated that this phosphorylation generates a docking site for inhibitory 14-3-3 proteins and is required for AMPK-mediated inhibition of mTORC1 (27). It appears that AMPK possesses at least two different ways to release the mTORC1-mediated repression on autophagy induction in case of alarming energy states.

The mechanism by which TORC1 negatively regulates the autophagic machinery has first been described in yeast. Genetic screenings for autophagy defective mutants led to the identification of more than 30 essential autophagy-related genes (Atg) (34, 81). It turned out that most of these Atg proteins are recruited to a single preautophagosomal structure (PAS) in a hierarchical manner upon starvation (97, 98). These proteins can be classified into several groups depending on their function and interdependency (81). Most upstream is a protein complex that comprises the serine/threonine kinase Atg1, as well as two accessory proteins Atg13 and Atg17. This complex is directly regulated by TORC1 in a nutrient-dependent manner (14, 49, 50). Although counterparts of this complex could be identified in mammals and flies over the last years, their regulation seems to differ in several ways from the situation in yeast (Fig. 1).

**ULK1/2: THE AUTOPHAGY INITIATORS**

Under optimal growth conditions, activated TORC1 inhibits autophagy induction in yeast by direct phosphorylation of Atg13 at several serine residues (Fig. 1). This hyperphosphorylation prevents binding to Atg1 and, hence, Atg1-Atg13-Atg17 complex formation (51). TORC1 inactivation, as resulting from nutrient deprivation or rapamycin treatment, in turn leads to immediate dephosphorylation of Atg13, to complex assembly and finally to...
FIG 1 Regulation of autophagy induction by the TOR and AMPK complex in yeast, flies, and mammals. (A) Under nutrient-rich conditions, activated TORC1 inhibits autophagy induction in yeast through direct phosphorylation of Atg13. This hyperphosphorylation of Atg13 prevents binding to Atg1. Inactivation of TORC1, as induced by starvation or rapamycin treatment, results in rapid dephosphorylation of Atg13, leading to the formation of the active Atg1–Atg13–Atg17 kinase complex (50, 51). The Atg13-mediated dimerization of Atg1 has recently been described to be essential for the autophosphorylation and subsequent activation of Atg1 (114). Furthermore, Snf1, a yeast ortholog of mammalian AMPK, has been found to be a positive effector of autophagy, presumably through regulation of Atg1 and Atg13 (107). (B) In contrast to yeast, the Atg1–Atg13 complex is stable under nutrient-rich conditions in Drosophila and dTORC1 phosphorylates both Atg13 and Atg1. In starved animals or when dTORC1 is specifically inhibited, these sites are dephosphorylated, Atg1 kinase activity is elevated, thus leading to autophosphorylation and phosphorylation of Atg13 (10, 11). Snf4a, y, a Drosophila ortholog of the mammalian AMPK gamma subunit, was found to be an inducer of autophagy; nevertheless, the exact mechanism remains elusive (68). (C) In mammals, two orthologs of yeast Atg1, termed Ulk1 and Ulk2, have been linked to starvation induced autophagy. Both are found in a stable complex with Atg13, FIP200 (5, 26, 28, 29, 37, 47), and Atg101, an additional binding partner of Atg13 that has no ortholog in yeast (38, 78). In contrast to yeast, the composition of this complex does not change with the nutrient status. Under fed conditions mTORC1 phosphorylates Ulk1/2 and Atg13, thereby inhibiting the kinase complex (26, 37, 47). In response to starvation, the mTORC1-dependent phosphorylation sites in Ulk1/2 are rapidly dephosphorylated, and Ulk1/2 autophosphorylates and phosphorylates Atg13 and FIP200. Alternatively, Ulk1/2 is phosphorylated by AMPK and thereby activated (20, 54). In addition, AMPK indirectly leads to the induction of autophagy by inhibiting mTORC1 through phosphorylation of raptor (27, 64). Note, however, that this is a schematic overview, and we do not provide any determination regarding the association between AMPK and the Ulk1/2–Atg13–FIP200 complex due to the conflicting results published in the recent past. For further details, see the legend to Fig. 3. (This figure was adopted and modified with permission from reference 11.)
recently generated *ulk1−/−ulk2−/−* mice do display early neonatal lethality (13). MEFs from these mice show a complete blockage of autophagy induction upon amino acid withdrawal but did respond to increasing ammonia concentrations, as a result from enhanced amino acid metabolism after long-term glucose withdrawal (13). Thus, it is well conceivable that autophagy in vertebrates can be induced either selectively or simultaneously by several partially overlapping signaling pathways, depending on the exact autophagic stimulus. Some of these pathways might even be independent of Ulk1 and Ulk2, as shown for *ulk1−/−ulk2−/−* MEFs (13) and *ulk1−/−ulk2−/−* DT40 cells by our group (1).

Although there is no clear Atg17 homolog in higher eukaryotes, the focal adhesion kinase (FAK) family-interacting protein of 200 kDa (FIP200), also called retinoblastoma 1-inducible coiled-coil 1 (RB1CC1), has been proposed as the functional counterpart of Atg17 (28, 29). FIP200 is a multifunctional protein that possesses several interaction partners and regulates diverse cellular processes such as cell growth, proliferation, cell spreading, and migration (reviewed in reference 25). FIP200 additionally interacts with Ulk1 and Ulk2, promotes Ulk1 kinase activity, translocates to the pre-autophagosomal membrane after starvation, and is essential for autophagy induction (29). A weakly conserved mammalian homolog of yeast Atg13 was first predicted by a sequence homology search (75), and its relevance for autophagy induction was subsequently confirmed by Chan et al. (10).

However, in contrast to the yeast Atg1-Atg13-Atg17 complex, the binding affinity between unc-51-like kinase 1/2 (Ulk1/2), Atg13, and FIP200 is largely unaffected by the nutrient status (Fig. 1). Instead, these proteins form a large and stable complex of the binding affinity between unc-51-like kinase 1/2 (Ulk1/2), top of which Ulk1 and that it prevents the proteasomal degradation of Atg13 (38, 78). The product of the mammalian C12orf44 gene has been identified as an additional component of the Ulk1/2-Atg13-FIP200 complex and as direct binding partner of Atg13 (38, 78). It has no obvious homolog in yeast and was accordingly named Atg101. Although its exact function is unknown thus far, the data suggest that it is crucial for basal phosphorylation of Atg13 and Ulk1 and that it prevents the proteasomal degradation of Atg13 (38, 78).

There is a significant body of evidence that the phosphorylation status within the Ulk1/2-Atg13-FIP200 complex dramatically changes with the nutrient status. Under normal growth conditions, mTORC1 associates with the Ulk1/2-Atg13-FIP200 complex, via direct interaction between raptor and Ulk1/2 (37). The active mTOR phosphorylates Atg13 and Ulk1/2 (26, 37, 47), thereby suppressing Ulk1/2 kinase activity. Under starvation conditions or when mTORC1 activity is pharmacologically inhibited, these sites are rapidly dephosphorylated by yet unknown phosphatases. Using stable isotope labeling with amino acids in cell culture (SILAC), Shang et al. could recently identify several serine and threonine residues in human Ulk1 whose phosphorylation was decreased after starvation (see Fig. 3). The most prominent decrease was detected at S638 and S758 and could be verified after rapamycin treatment and mTOR knock-down (95). Notably, S757 in mouse Ulk1 (corresponding to S758 in human Ulk1) was additionally identified as mTOR site by Kim et al. (35). The activated Ulk1/2 autophosphorylates and phosphorylates both FIP200 and Atg13, which in turn leads to translocation of the entire complex to the pre-autophagosomal membrane and to autophagy induction (8, 10, 26, 29, 37, 47) (Fig. 1). However, the functional relevance of Ulk1/2-mediated phosphorylation of Atg13 and FIP200 for this recruitment and the relevant phosphorylation sites have not been verified yet. Notably, although our group was able to identify five Ulk1-dependent *in vitro* phosphorylation sites in human Atg13, the mutation of these sites did not affect Atg13 function in DT40 cells (1). Furthermore, the mTORC1-dependent phosphorylation sites in mammalian Atg13 are still unknown and a recent mass spectrometric approach failed to identify nutrient-regulated *in vivo* phosphorylation sites in human Atg13 (96). Thus, it is still an exciting task to identify the exact *in vivo* phosphorylation sites within this complex and to explore their functional relevance. Interestingly, another Ulk1-dependent phosphorylation site in human Atg13 (S318) has been identified recently (46). The authors of that study could show that the Hsp90-Cdc37 chaperone complex selectively stabilizes and activates Ulk1. The activation of Ulk1 leads to phosphorylation of Atg13 and in turn to the independent translocation of Atg13 to depolarized mitochondria. However, although the expression of a nonphosphorylatable S318A mutant inhibited the selective clearance of damaged mitochondria in a dominant-negative way, it did not affect basal or starvation-induced autophagy (46). This mechanism might further explain the specific role of Ulk1 for mitochondrial clearance during reticulocyte maturation, as described above.

Furthermore, the existence of a mechanism for the selective elimination of damaged mitochondria (reviewed in reference 116) that can occur even under nutrient-rich conditions generally increases the complexity of autophagy regulation, especially since mitochondria are the major site of ATP and ROS production and the loss of mitochondrial membrane potential is an important trigger of apoptotic cell death pathways (99). Thus, it is conceivable that some *in vitro* conditions, widely considered as starvation, do not resemble physiological starvation conditions *in vivo* and instead massively interfere with mitochondrial homeostasis.

In yeast, autophagosomes originate from a single pre-autophagosomal structure. Although an equivalent structure seems to be absent from mammalian cells, a special subdomain in the endoplasmic reticulum (ER) termed the “omegasome” has been suggested as a putative origin of autophagosomes (3, 33, 115). This structure is enriched in PI(3)P, a product of the phosphatidylinositol 3-kinase (PI3K) class III complex. A hierarchical analysis of the mammalian Atg proteins could recently confirm the recruitment of Ulk1 proximal to these omegasomes (45). The translocation of Ulk1, presumably in a complex with Atg13 and FIP200, is the initial step of autophagosome biogenesis and is completely abrogated in *FIP200−/−* MEFs (45). The subsequent recruitment of the PI3K class III complex depends on Ulk1 and its kinase activity (45, 74).

Interestingly, various subunits of the AMPK complex have been identified as additional components of the Ulk1 kinase network (5), and several studies could meanwhile confirm the direct interaction between AMPK and Ulk1 as well as a positive regulation of Ulk1 activity through AMPK-dependent phosphorylation (21, 55, 64, 95). The AMPK-mediated phosphorylation of Ulk1 and the partially conflicting results have recently been discussed in a detailed commentary by Roach (88) and are summarized in Fig. 3. This further enlarges the range of possibilities for AMPK to induce autophagy, in addition to the more indirect AMPK-mediated regulation of mTORC1 activity via phosphorylation of Raptor and TSC2 (27, 44). Bach et al. could recently integrate...
some of the above mentioned findings (21, 95) by confirming S555 in Ulk1 as a major AMPK-dependent phosphorylation and 14-3-3 binding site (4). Interestingly, these authors could further identify S774 in Ulk1 as a potential Akt phosphorylation site, whose phosphorylation was enhanced by insulin treatment (4). Thus, Ulk1 (and presumably Ulk2) are direct targets of multiple kinases that might affect Ulk1/2 function in multiple, not mutually exclusive ways. It might induce conformational changes, thereby regulating Ulk1/2 kinase activity, the interaction with other regulatory components, such as 14-3-3 proteins, AMPK, and mTORC1, and/or affect the subcellular localization of the Ulk1/2-Atg13-FIP200 complex.

Although both mTORC1 and AMPK are able to oppositely regulate Ulk1 (and Ulk2) kinase activity by direct phosphorylation, the intriguing question remains how exactly Ulk1 activity is linked to autophagy induction. Two alternative mechanisms have been proposed recently. One report suggests that Ulk1 directly phosphorylates AMBRA1, a Beclin1-interacting protein and regulatory component of the PI3K class III complex (17, 22). Under normal growth conditions, the PI3K complex associates with the dynein motor complex via direct interaction between AMBRA1 and dynein light chain 1 (DLC1). Upon starvation, activated Ulk1 phosphorylates AMBRA1; thereupon, the PI3K complex is released and translocates to the ER, where it initiates autophagosome formation (17). Another group reported that dAtg1 and Ulk1 are able to regulate the actin motor protein myosin II (100). In Drosophila, dAtg1 directly phosphorylates and activates the myosin light-chain kinase (MLCK) Spaghetti-squash activator (Sqa). The depletion of Sqa and its mammalian homolog zipper-interacting protein kinase (ZIPK, also known as DAPK3), which is likewise phosphorylated by Ulk1, attenuated myosin II activation and starvation-induced autophagy (100). Notably, ZIPK knockdown and myosin II inhibition in addition significantly inhibited the redistribution of mAtg9 from the TGN to a peripheral pool upon starvation (100). The Ulk1- and Atg13-dependent cycling of the transmembrane protein mAtg9 from a juxtanuclear to a dispersed cytosolic pool in response to nutrient deprivation has been reported before (9, 117). This is similar to the situation in yeast, where Atg9 cycles from peripheral structures to the PAS in an Atg1- and Atg17-dependent manner upon autophagy induction (87, 93). Although Atg9 is essential for autophagy induction, its exact function is still unknown. However, it has been suggested that shuttling of mAtg9 from the Golgi apparatus helps to provide membranes for the newly formed autophagosomes (117). These two mechanisms are not mutually exclusive, since Ulk1 might act at several stages of autophagy initiation and regulate both mAtg9 trafficking and recruitment of the PI3K class III complex to the ER in order to initiate autophagosome generation.

mTOR AND ULK1/2: SPLIT PERSONALITIES?

Like any stable system, living cells strictly depend on negative feedback loops to retain the internal control. Although autophagy constitutes a rescue mechanism for starving cells and helps to get rid of superfuous material, prolonged and immoderate consumption of intracellular components necessarily causes severe side effects. Indeed, while mTOR is inactivated at early stages of autophagy induction, long-term starvation leads to reactivation of mTOR activity by enhanced autophagyososomal generation of nutrients. This in turn results in a slow-down of the autophagic machinery (118). Prolonged inhibition of autophagy on the other hand results in accumulation of protein aggregates and damaged organelles, causing pathological disorders such as neuro- and myodegenerative diseases (67). In Drosophila, chronic activation of dTOR hence increases FoxO transcription factor-mediated sestrin (dSesn) expression. The resulting AMPK-dependent inhibition of TOR in turn helps to prevent pathological long-term TOR hyperactivation (63).

Resembling the ambivalent nature of autophagy, mTORC1 not only inactivates the Ulk1/2-Atg13-FIP200 complex as described above, thereby inhibiting autophagy, but also simultaneously phosphorylates and inactivates the protein DAPI. Astonishingly, DAPI turned out to be a repressor of autophagy, since its knockdown enhances the autophagic flux (57). During starvation, the mTORC1-dependent sites are rapidly dephosphorylated and DAPI antagonizes autophagy induction in an as-yet-unknown manner (57). Thus, the current data suggest that mTORC1 inhibition, although activating the autophagic machinery, simultaneously contributes to the prevention of unrestrained autophagic degradation.

In line with that, our group could show that activated Ulk1 directly phosphorylates AMPK and inhibits its activation, thus providing another potential negative-feedback loop on autophagy induction (70).

Several studies could demonstrate that Ulk1 in addition directly interferes with mTORC1 signaling and negatively regulates S6K1 activity, both in Drosophila and mammalian cells (65, 92). While phosphorylation of the dTOR-downstream target S6K was almost completely inhibited after Atg1 overexpression (92), it was strongly enhanced in Atg1-deficient fly mutants (65). Recently, two groups found evidence for the mechanism by which Ulk1 and Ulk2 negatively regulate mTORC1 signaling. It was already known that mTORC1 associates with the Ulk1/2-Atg13-FIP200 complex, via direct interaction between raptor and Ulk1/2, and negatively regulates Ulk1/2 kinase activity by direct phosphorylation (10, 26, 37, 47, 55). Vice versa, the phosphorylation of raptor is strongly enhanced after overexpression of Ulk1 (19, 48), presumably by direct phosphorylation of raptor at numerous sites (19). Interestingly, one of these residues (T792) is the above-mentioned effector site through which AMPK negatively regulates mTORC1 activity (27). The multiple Ulk1-dependent phosphorylation of raptor, which either results in direct inhibition of mTORC1 kinase activity (48) or interferes with raptor-substrate interaction (19), thus finally leads to reduced phosphorylation of mTORC1 downstream targets.

THERAPEUTIC IMPLICATIONS

Recently, autophagy has evolved as one of the central topics in cancer research. However, the role of autophagy during tumorigenesis and tumor progression is far from being completely understood. Interestingly, both the induction and the inhibition of autophagy have been reported to be beneficial for the patient. Whereas the inhibition of autophagy appears to increase the responsiveness of tumor cells toward conventional anticancer drugs, the induction of autophagy may induce cell death in tumor cells with high intrinsic apoptosis resistance. The ambivalent role of autophagy in cancer biology and the emergence of autophagy pathways as novel targets for drug development in anticancer therapy have been extensively reviewed in recent publications (1a, 6, 16, 66, 69, 73, 104).
Regarding the interplay between AMPK, mTOR, and Ulk1/2 described above, these kinases represent an attractive target for therapeutic treatment. To date, especially mTOR has been in the focus of anticancer therapeutic strategies (reviewed in references 20 and 79). However, although mTOR signaling is frequently dysregulated in cancer, rapamycin analogs do not show any considerable activity as single agents in many tumor types and thus are often used in combination therapy (79). This might be partially due to the rapamycin-resistant functions of mTORC1, as mentioned previously (20, 101, 102), and could thus be overcome by...
FIG 3 Mutual phosphorylation of Ulk1, mTORC1, and AMPK. (A) Ulk1 is a hyperphosphorylated protein that is massively dephosphorylated upon starvation. Under normal growth conditions, mTORC1 has been shown to directly bind to and negatively regulate Ulk1/2 kinase activity by direct phosphorylation (26, 37, 47). A total of 16 phosphorylation sites in mouse Ulk1, purified from HEK293T cells under fed conditions, were first mapped by Dorsey et al. (18). These authors additionally identified two sites, differentially phosphorylated in wild-type versus kinase-dead Ulk1 (S1043 and S1047). While the one was suggested as direct target for autophosphorylation, the other might represent a putative PKA site (18). Shang et al. (95) quantitatively analyzed the differential phosphorylation status in human Ulk1 purified from HEK293T cells between fed versus starved conditions (HBSS containing 1% rich medium) using stable isotope labeling with amino acids in cell culture (SILAC). A total of 13 sites were identified, with the strongest dephosphorylation at S638 and S758 (corresponding to S637 and S757 in mouse Ulk1) showing a >10-fold decrease after starvation, although with different kinetics. The same decrease was seen after rapamycin treatment and mTOR knockdown (95). Interestingly, phosphorylation at S638 was affected by the knockdown of AMPK and AMPK (95). Shang et al. found that AMPK was associated with Ulk1 under fed conditions and proposed that the dephosphorylation of S758 seen after starvation is critical for the dissociation of AMPK/Ulk1. In contrast, Lee et al. (64) proposed that the interaction between AMPK and Ulk1 is essential for the induction of autophagy and that AMPK activity both recruits 14-3-3 proteins to the complex and leads to inactivation of mTORC1 activity by AMPK-mediated phosphorylation of raptor at S792 (27, 64). Egan et al. (21) additionally identified Ulk1 both as an AMPK substrate and as a 14-3-3 binding protein. This group found S467, S555, T574, and S637 of Ulk1 to be phosphorylated after phenformin treatment and confirmed these sites in an AMPK in vitro kinase assay (21). Notably, Bach et al. (4) could meanwhile confirm the AMPK-dependent phosphorylation at S555 and that this induces the binding to 14-3-3 proteins. This group additionally identified a critical phosphorylation site in the Ulk1 activation loop (T180), as well as a potential Akt phosphorylation site (S774) whose phosphorylation is increased after insulin treatment. The phosphorylation and differential regulation of Ulk1 by mTORC1 and AMPK has also been reported by Kim et al. (55). This group identified S757 in mouse Ulk1 as a direct mTOR site, the same identified by Shang et al. in human Ulk1 (95). However, Kim et al., in contrast, suggest that phosphorylation at S757 prevents the interaction between Ulk1 and AMPK. mTORC1 inhibition would thus lead to an association of AMPK and Ulk1. In line with that, the data suggest an activating effect of AMPK on Ulk1 kinase activity by direct phosphorylation at S537 and S777. These authors found that both sites are required for Ulk1 activation after glucose starvation (55). Notably, neither of these two sites has been identified by one of the other groups. All phosphorylation sites identified by the five groups (4, 18, 21, 55, 95) are shown in single-letter code and refer to mouse Ulk1. Proposed kinases are either indicated by name or otherwise labeled with question marks (?). (B) Dunlop et al. (19) and Jung et al. (48) identified raptor as a direct substrate of Ulk1 and Ulk1 thereby as a negative regulator of either mTORC1 activity (48) or substrate binding (19). After overexpression of Ulk1, Dunlop et al. observed an increase in the in vivo phosphorylation of raptor at S696, T706, S792, S855, S859, and S863 using phospho-specific antibodies and could subsequently confirm the latter four sites as directly phosphorylated by Ulk1 (19). The strongest phosphorylation was seen on S859. Interestingly, S792 is the AMPK and 14-3-3 binding site identified by Gwinn et al. (27), by which AMPK negatively regulates mTORC1 activity, while S863 is known to be phosphorylated by mTOR and to promote mTORC1 activity (23, 106). (C) Löffler et al. (70) identified all three subunits of AMPK as a direct substrate of Ulk1 and Ulk2 and mapped several Ulk1-dependent in vitro phosphorylation sites in AMPKα1, -β2, and -γ1 (residues refer to rat AMPK, for some peptides the phospho-acceptor sites could not be distinguished: S360/T368, S486/T488, and S260/T262). The Ulk1-dependent phosphorylation of AMPK has been proposed to negatively regulate AMPK kinase activity, thus constituting a negative regulatory feedback loop (70). (This figure was adopted and modified with permission from reference 88.)
inhibitors that directly target the catalytic activity of mTOR (20). However, keeping the complex network of regulation involving cross talks and feedbacks, as well as the ambivalent nature of autophagy in mind, both the activation and the inhibition of these three kinases (kinase complexes) might be desirable, and a better understanding of their interplay during the regulation of autophagy will hopefully allow us to design tumor-specific and tumor stage-specific therapies.

CONCLUSION
The orchestration of the cellular metabolism is not conducted by a single leader; the complex protein network itself precisely senses demand and supply and appropriately responds even to conflicting requirements by self-organization. Effective teamwork, however, depends on frequent and extensive communication within the team. Collectively, the above-described results point out an astonishingly complex interplay between AMPK, Ulk1/2–Atg13–FIP200, and mTORC1, comprising both positive- and negative-feedback regulation. mTORC1 and AMPK are able to oppositely regulate Ulk1/2 kinase activity by direct phosphorylation. On the other hand, Ulk1 can both negatively regulate mTORC1 activity by direct phosphorylation of raptor and negatively regulate AMPK activity by multiple phosphorylation of all three AMPK subunits (Fig. 2 and 3). Although we are just beginning to understand the details of this mutual regulation, the extensive cross talk might help to accurately coordinate cell growth and the increasing demand of energy and nutrients with regard to fluctuations in their external supply and the need of internal production by autophagic degradation.

The growth of unicellular organisms such as yeast largely depends on the external availability of oxygen and suitable carbon and nitrogen sources. Autophagy therefore represents an accurate way to rapidly adapt to decreasing external concentrations. The growth and proliferation of cells from multicellular organisms, however, that benefit from a relatively constant supply with nutrients is additionally regulated by hormones and growth factors (Fig. 2). These factors regulate the differential uptake of nutrients by specific cell types, the apoptotic cell death of individual cells, and the cell type-specific fate during development. This impressively reflects the subordination of the individual cell fate to the need of the whole organism. Furthermore, the autophagic machinery, once invented by unicellular eukaryotes, has been adopted for additional purposes during evolution, such as development (76), as well as adaptive and innate immunity (15, 24). Autophagy regulation in metazoans is thus far more complex and inextricably interwoven with diverse signaling pathways that regulate cell death, cell survival, and tumor suppression. The obvious differences in regulation of autophagy induction between yeast, flies, and vertebrates (Fig. 1) and the existence of several partially redundant isoforms in vertebrates can thus be explained by the need to integrate and consider further variables. Although negative-feedback circuits prevent the system from overriding, redundancy in protein function and signaling pathways might provide a safety mechanism that prevents the system from failure. However, since multicellular organisms comprise hundreds of cell types with specialized function, this redundancy might simply reflect the different routes preferentially taken by different cell types.

ACKNOWLEDGMENTS
We thank Stephan Mumm for carefully reading the manuscript. This study was supported by grants from the Deutsche Forschungsgemeinschaft SFB 773 and GRK 1302 and from the Interdisciplinary Center of Clinical Research, Faculty of Medicine, Tübingen, Germany (Nachwuchsgruppe 1866–0–0).

REFERENCES


Mizushima N. 2006. ATG1, an autophagy regulator, inhibits cell growth by negatively regulating S6 kinase. EMBO Rep. 8:360–365.


96. Shang L, Wang X. 2011. AMPK and mTOR coordinate the regulation of Ulk1 and mammalian autophagy initiation. Autophagy 7:924–926.